Bayer Investor Relations

Team having a chat

Events /// Investor News /// Investment Case /// Resources

 

Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders. 

Investor News
Share Price / Index
March 23, 2026
Not intended for U.S. and UK Media
Eylea™ 8 mg approved for third retinal indication in Japan
March 23, 2026
First approval for Bayer’s low-dose MRI contrast agent in Japan
March 16, 2026
Not intended for U.S. and UK Media
Finerenone meets primary endpoint in pivotal Phase III FIND-CKD study in patients with non-diabetic chronic kidney disease